HIV vaccine enters human efficacy trials

Multimedia · Fri Oct 05 00:00:00 EDT 2018

OSTI ID:1487129

Korber, Bette

The HIV mosaic vaccine was originally designed at Los Alamos National Laboratory using a machine learning algorithm designed by Bette Korber and her team. It's the first computationally designed HIV vaccine. Through a decade of testing, it has shown promise and is now in human efficacy trials. The study will evaluate whether the investigational vaccine regimen is safe and able to reduce the incidence of HIV infection among 2,600 sexually active women in sub-Saharan Africa. The new study, HVTN 705/HPX2008, is known as “Imbokodo,” the Zulu word for “rock,” from a South African saying that refers to the strength of women and their importance in the community.

• Research Organization: Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
• Sponsoring Organization: USDOE National Nuclear Security Administration (NNSA)
• OSTI ID: 1487129
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
HIV MOSAIC VACCINE
IMBOKODO
TRANSMISSIBLE DISEASE
MACHINE LEARNING
HIV GENOME DATABASE
COMPUTER-GENERATED VACCINE SEQUENCE